Millennium Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Millennium Management’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,622	Closed	-$19K	–	7025
2023 Q1	$19K	Sell	1,622 -848	-34%	-$11.3K	﹤0.01%	5887
2022 Q4	$36K	Sell	2,470 -1,560	-39%	-$52.2K	﹤0.01%	5891
2022 Q3	$202K	Buy	4,030 +995	+33%	+$69.2K	﹤0.01%	5658
2022 Q2	$259K	Buy	+3,035	New	+$260K	﹤0.01%	5480
2022 Q1	–	Sell	-421	Closed	-$126K	–	7821
2021 Q4	$126K	Buy	+421	New	+$161K	﹤0.01%	6160
2021 Q3	–	Sell	-2,171	Closed	-$917K	–	7438
2021 Q2	$917K	Sell	2,171 -4,706	-68%	-$2.04M	﹤0.01%	4743
2021 Q1	$3.28M	Buy	+6,877	New	+$3.5M	﹤0.01%	3039

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Millennium Management's FNCH Position: Q2 2023 in Review

Millennium Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 1,622 shares — an estimated $19K sold.

Millennium Management first reported a position in FNCH in Q1 2021 and held it in 7 quarters. The position peaked at $3.28M in Q1 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Millennium Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 1,622 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $19K.
Millennium Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Millennium Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $3.28M in Q1 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.